Kevzara® (sarilumab) approved by fda for the treatment of active polyarticular juvenile idiopathic arthritis (pjia)

Approval in patients with pjia weighing 63kg or greater adds to kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica
REGN Ratings Summary
REGN Quant Ranking